NuWays sets EUR 21.50 target for Eckert & Ziegler stock

Published on 10/23/2026 at 10:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NuWays expects EUR 78.80 million in third-quarter revenue. Eckert & Ziegler stock costs EUR 13.33 on October 23, 2026, 0.23 percent above Xetra close.

Business developments and dates

On October 13, 2026, Eckert & Ziegler and TerThera signed a Tb-161 supply agreement for Brazil.
NuWays projected EUR 78.80 million in third-quarter revenue and EUR 18.20 million in adjusted EBIT on October 19, 2026.
Eckert & Ziegler stock trades at EUR 13.33 at 10:33 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.23 percent above the Xetra close of October 22, 2026.

Bauhaus-Designposter mit geometrischen Formen, Primärfarben und MEDTECH-Schriftzug — Eckert & Ziegler DE0005659700 Medizintechnik: Bauhaus-Poster mit geometrischen Grundfarben und Atomstruktur-Motiv sowie MEDTECH-Sektor-Schriftzug, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) is facing a NuWays valuation test with a EUR 21.50 twelve-month price target and a Buy rating. The analyst forecast centers on third-quarter revenue of EUR 78.80 million and adjusted EBIT of EUR 18.20 million, according to Stock-World on October 20, 2026.

Supply agreement broadens the story

On October 13, 2026, Eckert & Ziegler Brazil and TerThera signed a strategic agreement for GMP-compliant, non-carrier-added Terbium-161. The agreement is intended to support radioligand therapies and local research in Brazil, as reported by EQS News. The release identifies Eckert & Ziegler as a TecDAX company and confirms the ISIN.

The chronology shows three recent reference points. On October 13, 2026, the Terbium-161 agreement added a Brazil supply initiative. On October 19, 2026, NuWays presented EUR 78.80 million of expected third-quarter revenue and EUR 18.20 million of adjusted EBIT. On October 20, 2026, the published preview said those estimates would be tested by the upcoming report, according to Stock-World.

What will the report need to prove?

The key issue is profit quality rather than revenue alone. NuWays expects improvement in Isotope Products, higher Lu-177 sales and license income, but the EUR 18.20 million adjusted EBIT figure remains an analyst estimate rather than reported company performance.

For comparison, second-quarter 2026 revenue was EUR 76.40 million, down 5.20 percent from the second quarter of 2025, while net income reached EUR 12.00 million, up 2.50 percent, according to Simply Wall St. That history makes the adjusted EBIT outcome the more important measure for testing the latest expectations.

Dates investors can measure

Eckert & Ziegler is scheduled to publish its third-quarter financial report on November 12, 2026. The company calendar also lists the annual financial report for March 24, 2027, according to EQS News.

Stock stays below its yearly high

The stock remains EUR 4.40 below its 52-week high of EUR 17.73 and EUR 1.42 above its 52-week low of EUR 11.91. Market capitalization was EUR 833.5 million as of October 23, 2026, putting the analyst target well above the current euro quotation.

Eckert & Ziegler was trading at EUR 13.33 at Lang & Schwarz on October 23, 2026 at 10:33 a.m. CEST, plus 0.23 percent versus the Xetra close of October 22, 2026 at EUR 13.30. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.